{"id":"W4211106526","doi":"10.1158/1078-0432.ccr-21-3045","title":"Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; National Institutes of Health; Breast Cancer Alliance; Sierra Oncology; Ipsen; Genentech; Deutsche Krebshilfe; G1 Therapeutics; Stand Up To Cancer; EMD Serono; Mersana Therapeutics; Merck KGaA; Dana-Farber/Harvard Cancer Center; GlaxoSmithKline; Breast Cancer Research Foundation; Pfizer; Symphogen; Carrick Therapeutics; American Association for Cancer Research; AstraZeneca; Eli Lilly and Company; Astex Pharmaceuticals","keywords":"Olaparib; PARP inhibitor; Clinical trial; Breast cancer; Cancer; Phases of clinical research; Poly ADP ribose polymerase","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005262504,0.0003990364,0.001412199,0.0002685124,0.0007924484,0.00006094137,0.0005747518,0.000230868,0.003155541],"category_scores_gemma":[0.001184386,0.0002937183,0.0004282995,0.001317168,0.001448153,0.0002404195,0.0002553223,0.002987245,0.00002007966],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001666062,"about_ca_system_score_gemma":0.005866092,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000432308,"about_ca_topic_score_gemma":0.0002975666,"domain_scores_codex":[0.9914276,0.001502591,0.001727736,0.001534454,0.002620842,0.001186757],"domain_scores_gemma":[0.9911167,0.004059516,0.0005642879,0.0009921896,0.002392141,0.0008751495],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8375576,0.01150026,0.0168566,0.00009673581,0.0006512612,0.00003908559,0.0002097668,0.00009600284,0.00001795593,0.00007446827,0.03528186,0.09761837],"study_design_scores_gemma":[0.8135908,0.07038568,0.01791561,0.0003646307,0.0002421281,0.00001173389,0.0003989478,0.0004151257,0.0001017269,0.0002205401,0.09582731,0.0005257607],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9766904,0.0005687833,0.000234069,0.006092486,0.002134954,0.01016617,0.003423578,0.0001189835,0.0005705669],"genre_scores_gemma":[0.9713836,0.001114907,0.001022283,0.002831713,0.003482232,0.01708046,0.0002898148,0.0001878439,0.00260714],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09709261,"threshold_uncertainty_score":0.9999515,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2879403571378599,"score_gpt":0.59430337590085,"score_spread":0.3063630187629901,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}